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In 1868, Flint described a condition called ‘‘chronic
pneumonitis’’ and noticed that the ﬁngertips of one
patient assumed a bulbous appearance.1,2 This was
probably the ﬁrst recorded case of the condition
we now recognise as idiopathic pulmonary ﬁbrosis
(IPF), formerly known as cryptogenic ﬁbrosing
alveolitis. IPF has continued to puzzle and frustrate
clinicians in equal measures over the years, and
remains an enigma. It is an important, and
devastating, disease, with a median mortality of 3
years, worse than many cancers,3 and its incidence
continues to rise, doubling in just over a decade.4
We will begin in the past, highlighting lessons
from the last century that are still having relevanceElsevier Ltd. All rights reserv
4 551210.
s.net.today. Key papers, some of which have been
published in Respiratory Medicine, and its fore-
runners, will be cited, in this Centennial issue.
Thereafter, we will turn to the present day,
assessing how much we know about IPF and the
role of current therapies and management. Finally,
an overview of exciting potential therapies that are
beginning to emerge in well-designed trials will be
provided, and we will try and predict what the
future holds for this group of patients who continue
to have great clinical need.Methods
A comprehensive literature search using Medline,
Clinical Evidence, Cochrane library and EMBASE
was performed. In addition, issues of Respiratory
Medicine and its forerunners since 1907 (Britished.
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losis and Diseases of the Chest, British Journal of
Diseases of the Chest) were also reviewed. Pub-
lished articles, and articles in press, available up to
July 2006, were then selected and extracted, along
with papers which the author felt to be topical, and
of interest to clinicians.Figure 1 The photograph shows a large ﬁbroblastic focus
(arrow) in an area of interstitial chronic inﬂammation,
located beneath epithelial cells that line the luminal
surface (magniﬁcation  200).Deﬁnitions and classiﬁcation
The interstitium is the microscopic space between
the basement membranes of the alveolar epithelium
and capillary endothelium, and forms part of the
blood–gas barrier. Idiopathic interstitial pneumonias
(IIPs) are characterised by expansion of the inter-
stitial compartment by inﬂammatory cells, with
associated ﬁbrosis in many cases.5 The most recent
international classiﬁcation, published in 2002, di-
vides IIPs into seven distinct groups—IPF, non-
speciﬁc interstitial pneumonia (NSIP), respiratory
bronchiolitis interstitial lung disease (RBILD), des-
quamative interstitial pneumonia (DIP), acute inter-
stitial pneumonia (AIP), cryptogenic organising
pneumonia (COP) and lymphoid interstitial pneumo-
nia (LIP).6 IPF is the most common form, accounting
for approximately 60% of cases and is associated
with a classic pathologic pattern called usual
interstitial pneumonia (UIP).7 It is important to be
aware that in UIP, ‘‘pneumonia’’ is used to describe
inﬂammation (rather than infection), while ‘‘usual’’
indicates that the histological pattern is that most
commonly observed. A UIP pattern can be seen in
patients with other conditions (asbestosis, connec-
tive tissue diseases, chronic hypersensitivity pneu-
monitis, and certain drug-induced lung diseases) and
is not unique to IPF, although often the terms are
used synonymously.7Pathology
Key features include lower lobe and subpleural
predominance, geographical and temporal hetero-
geneity, relatively mild interstitial inﬂammation
with ﬁbrosis, typically with normal or only mildly
affected intervening lung.8 Ultimately this results
in chronic scarring with architectural distortion and
honeycombing. The distinctive ﬁbroblastic focus, a
hallmark lesion that is the site of active ﬁbrosis, is
not unique to UIP but is seen at the interface
between dense peripheral ﬁbrosis and more normal
lung centrally in the lobule (Fig. 1). Ground glass
opaciﬁcation is seen, but seldom extensive. Acute
exacerbations of IPF are associated with signs ofdiffuse alveolar damage, notably hyaline mem-
brane formation, hyperplastic type II alveolar cells,
and interstitial thickening secondary to oedema
and inﬂammatory/ﬁbroblastic cell inﬁltration.8,9Pathogenesis
The cause of IPF is unknown. Following Hamman
and Rich’s description in 1944 of what we would
now describe as AIP, the ‘‘inﬂammatory/alveolitis’’
hypothesis prevailed for several decades, the
assumption being that IPF was a chronic inﬂamma-
tory disease, occurring in response to an unknown
stimulus, and if left untreated, led to progressive
lung injury and ultimately ﬁbrosis.10,11 As discussed
later in this review, it is now clear that anti-
inﬂammatory agents have been disappointingly
ineffective in the management of IPF.12,13
The current ‘‘epithelial/mesenchymal’’ hypoth-
esis suggests that IPF results from multiple episodes
of epithelial cell activation from, as yet unidenti-
ﬁed, exogenous and endogenous stimuli.14 The
initial insult to the lungs is still unclear, and results
in disruption of the alveolar epithelium.15 Conse-
quently, migration, proliferation and activation of
mesenchymal cells occurs, resulting in the forma-
tion of ﬁbroblastic/myoﬁbroblastic foci (Fig. 1),
with excessive accumulation of extra-cellular ma-
trix, mirroring abnormal wound repair.14 The origin
of the ﬁbroblasts, key cells in the pathogenesis of
IPF, is still unclear, and is possible that extra-
pulmonary, as well as pulmonary progenitor cells
are involved in the aberrant repair/remodelling
process.16–19 This complex process is well-de-
scribed elsewhere and offers potential targets for
therapeutic intervention.14
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A comprehensive epidemiological overview has
recently been published, and it is clear that robust
data is largely lacking for IPF.20 Diagnostic impreci-
sion, changing disease classiﬁcation and hetero-
geneous study design have been responsible for
signiﬁcant variation in estimated incidence and
prevalence.
In one of the best population-based studies, from
Bernalillo County in New Mexico, Coultas et al.21
recorded all new cases of interstitial lung disease
registered over a 2-year period in a population of
nearly half a million inhabitants. Coultas et al.21
reported an incidence/prevalence (male/female)
per 105 population of 11/7 and 20/13, respectively.
A Norwegian study reported an incidence/prevalence
for hospitalised IPF of 4.3 and 20 per 1000000.22
In the UK, data has been analysed from a primary
care database of approximately 4 million patients,
with 962 cases of IPF identiﬁed between 1991 and
2003, excluding patients with connective tissue
diseases and adjusting for age and gender.4 The
incidence of IPF has been reported as rising by 11%
annually between 1991 and 2003, suggesting the
number of recorded diagnoses of IPF is doubling
every 8 years.4
Most studies suggest IPF is more common in
men,21,23,24 and is a disease predominantly of the
elderly, with a mean age of onset typically 67–69.21
Many potential risk factors have been suggested as
being linked with IPF,7 notably cigarette smoking,25
medication (anti-depressants),26 chronic aspira-
tion,27–29 metal and wood dusts 24,30,31 and infectious
agents.7,20,21 Viral infections suggested to be linked
with IPF include hepatitis C, adenovirus and Epstein–
Barr virus.32 In vivo, Epstein–Barr replication has been
reported to be signiﬁcantly increased within type II
alveolar epithelial cells in lung biopsies from patients
with IPF, compared to controls.33 Several studies have
suggested that IPF may be related to repeated
aspiration of gastric contents over long periods of
time and a recent study suggests that abnormal
gastro-oesophageal reﬂux is highly prevalent, but
often clinically occult, in patients with IPF.27–29
Familial IPF is rare, with a recent UK study
reporting a prevalence of 1.34 cases per million,
accounting for only 0.5–2.2% of all cases.34 A
Finnish study reported similar ﬁndings, with famil-
ial IPF accounting for 3.3–3.7% of cases.35 Cluster-
ing within families has been widely reported, and a
group of 111 families, with 309 affected indivi-
duals, has recently been described36 Interestingly,
phenotypic heterogeneity was seen in almost half
the families, with several subtypes of IIP reported,
suggesting that environmental factors are alsorelevant. Older age, male sex and having ever
smoked cigarettes were associated with developing
IPF.36 Associations between IPF and speciﬁc poly-
morphisms in genes encoding interleukin-1 recep-
tor antagonist, tumour necrosis factor-a and
complement receptor 1 have been reported.37
Furthermore, two mutations in the gene encoding
surfactant protein C have been identiﬁed, resulting
in protein misfolding, causing type II epithelial cell
injury.38,39 Susceptibility to IPF probably involves a
combination of genetic polymorphisms related to
epithelial cell injury and abnormal wound healing.
Gene expression proﬁle is now also being used to
identify target genes involved in tissue remodelling
and epithelial/mesenchymal differentiation.40,41Natural history and acute exacerbations
A diagnosis of IPF is associated with a median
mortality of approximately 3 years.3 Early studies
generally overestimated survival rates, and often
included patients with other forms of IIP such as
NSIP, which typically is associated with better
survival and more response to corticosteroids and
other therapies. The perception of IPF has, until
recently, been one of a disease that progresses at a
steady rate, but it is clear that many patients
experience a much more rapid decline, often
punctuated by precipitous, and often terminal
episodes, now termed ‘‘acute exacerbations’’.42
Indeed, acute exacerbations were found to precede
death in as many as 47% of patients in a recent
study of patients from the placebo arm of a large
trial.43 The speciﬁc diagnostic criteria deﬁning an
acute exacerbation are not yet agreed, but loosely
based on the criteria suggested by Kondoh et al.9
and include worsening dyspnoea or cough within
the last month, new ground-glass opacities or
consolidation on chest imaging studies, worsening
hypoxaemia and rapid development of respiratory
failure in the absence of infection, pulmonary
embolism, congestive heart failure, pneumothorax
or other obvious alternative diagnosis.9,44,45 Lung
biopsies usually show diffuse alveolar damage, as
described earlier.8 High ﬂow oxygen and empirical
intravenous methylprednisolone are often tried,
although evidence for the latter is limited to case
reports.46 One study has suggested that anti-
coagulation may also signiﬁcantly improve survival,
although the mechanism is unclear.47 The study had
signiﬁcant methodological ﬂaws and further studies
are needed before anti-coagulation is recom-
mended.45 Acute exacerbations are associated with
high mortality, with several studies reporting poor
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care unit.48,49 In one study, 92% of hospital survivors
died a median of 2 months after discharge.48Diagnosis
It is important to make a conﬁdent diagnosis of IPF
(Table 1), since this has implications for prognosis,
and allows the creation of a logical management
plan. Many other IIPs, notably NSIP, present identi-
cally to IPF, yet behave completely differently in
terms of steroid responsiveness and prognosis. There
is evidence to suggest that a dynamic, multidisci-
plinary approach results in better diagnostic out-
comes, and patients with IPF are increasingly being
managed in specialist clinics.50,51 This allows clinical,
physiological, radiological and histopathological data
to be viewed in context.Clinical features
Patients typically present with gradual onset,
progressive exertional dyspnoea, often initially
attributed erroneously to the ageing process, or
misdiagnosed as respiratory tract infection or
pulmonary oedema. Cough, often non-productive,
is also commonly a symptom. Alternatively, IPF is
detected incidentally in an asymptomatic patient,
when a chest radiograph is performed for other
medical problems. Clinical examination often, but
not always, reveals digital clubbing, with coarse
‘‘Velcro-’’ like crackles audible on auscultation
over lower lobes particularly. More advanced
disease is associated with signs of pulmonary
hypertension and cor pulmonale.Table 1 Diagnostic criteria for IPF in absence of surgica
Major criteria (all four features require to be present)
 Exclusion of other known causes of interstitial lung dise
and collagen vascular diseases
 Abnormal pulmonary function studies that include evid
exchange
 Bibasal reticular abnormalities with minimal ground gla
scan
 Transbronchial lung biopsy or bronchoalveolar lavage sh
Minor criteria (three out of four features must be present
 Age 450 years
 Insidious onset of otherwise unexplained dyspnoea on e
 Duration of illness 3 months
 Bibasal inspiratory crackles (dry or ‘‘Velcro-’’ type in qRadiological features
In early IPF, a chest radiograph is often normal.52
With disease progression, features such as reduced
lung volumes and predominantly peripheral and
basal ﬁbrotic changes become apparent. High-
resolution CT scanning is much more sensitive,
and is the major diagnostic advance in interstitial
lung disease over the last two decades. It allows
optimal visualisation of small structures such as
nodules, bronchial and cyst walls and inter/intra-
lobular septa and, if typical of UIP/IPF, often
obviates the need for surgical lung biopsies. Typical
features include a basal, peripheral predominance
and patchy reticular abnormality, with honeycomb-
ing.53 A normal HRCT scan virtually excludes the
diagnosis. Features such as signiﬁcant mediastinal
lymphadenopathy, ground-glass attenuation, cysts,
upper-lobe predominance, pleural plaques and
effusion, should raise the possibility of alternative
diagnosis. Inter-observer variability in reporting
HRCTs, between practising thoracic radiologists has
been assessed.54 Good agreement was found, with
weighted k values quantifying the likelihood of
speciﬁc diseases, moderate to good (mean 0.57,
range 0.49–0.70), but cases diagnosed with low
conﬁdence, particularly when NSIP was considered
as a differential diagnosis, were felt to beneﬁt from
the expertise of a reference panel.54Physiological features
Spirometry is classically restrictive in pattern,
although in early IPF may be deceptively normal.
Many patients have co-existing emphysema, which
further complicates interpretation of spirometryl lung biopsy.7
ase, such as drug toxicities, environmental exposures,
ence of restriction with or without impaired gas
ss opacities on high resolution computed tomographic
owing no features to support an alternative diagnosis
)
xertion
uality)
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typically reduced, before spirometry has become
abnormal. Desaturation during exercise during a 6-
min walk is another important ﬁnding, and is
relevant not only to grading disease severity, but
also in terms of predicting prognosis, as discussed
later in this review.56Other tests
Bronchoscopy with transbronchial biopsies and
lavage are of limited diagnostic value, but can
suggest alternative diagnoses, such as sarcoidosis,
infection, malignancy or organising pneumonia.57
Blood tests are generally non-speciﬁc, although
can suggest alternative diagnoses, such as sarcoi-
dosis (angiotensin converting enzyme) and vasculi-
tis/connective tissue disorders (strongly positive
anti-nuclear antibody, anti-neutrophil cytoplasmic
antibody, extractable nuclear antigens). Serum
biomarkers in interstitial lung disease, while still
a research tool, may have a role as prognostic and
diagnostic tools, and an excellent overview is
provided elsewhere.58 For example, circulating
levels of KL-6, a lung epithelium-speciﬁc protein,
have been shown to predict the efﬁcacy of
corticosteroids at an earlier time point than other
studied non-speciﬁc markers, when overall clinical
effect may not yet be evident.59 Furthermore, KL-6
has been compared to other serum biomarkers,
such as surfactant protein-A, surfactant protein-D
and monocyte chemoattractant protein-1, with
receiver operating characteristic curves suggesting
KL-6’s superiority as a biomarker.60Diagnostic criteria and the role of
surgical lung biopsy
Surgical lung biopsy is not necessary in all patients,
particularly if key HRCT, clinical and physiology
diagnostic criteria are present.7 (Table 1) If biopsies
are required, a video-assisted thoracoscopic ap-
proach is usually sufﬁcient.61,62 It is important that
biopsies are taken from several lobes, given UIP and
NSIP can co-exist in the same lung and the disease
is often patchy.3,63 General and pulmonary pathol-
ogists often differ in their interpretation of the
histopathology and this has clinical implications for
care.64 Patients with IPF generally tolerate surgical
lung biopsy well, although risk factors for those
likely to do poorly include, unsurprisingly, those
requiring mechanical ventilation or who are im-munosuppressed.65 There is a small (2%) risk of
postoperative acute exacerbations occurring.66Prognosis
Overall, the prognosis of IPF is poor, with a median
mortality typically of 3 years in several studies.67–70
The prognosis of an individual patient, however, is
more difﬁcult to deﬁne, with some patients
experiencing a precipitous decline after long
periods of relative stability.43 Advanced age and
male gender are associated with higher mortality.
Several prognostic physiological markers have
been suggested, either alone or in combina-
tion.71,72 The clinically useful concept of ‘‘limited’’
(gas transfer 440%) and ‘‘advanced’’ (gas transfer
o39%) disease has been suggested, with the latter
group likely to do poorly, and ideally referred
for transplant if otherwise a suitable candidate
(Fig. 2).56 In the ‘‘limited’’ disease group, serial
changes in pulmonary function appear to be
predictive of prognosis, with a fall in forced vital
capacity of 410% and gas transfer 415% being
associated with a poorer outcome, over rela-
tively short periods of assessment e.g. 6–12
months.56,73–77 It is interesting to note that similar
observations about the utility of longitudinal
pulmonary function assessment were being made
as long ago as 1972 by Benson and Hughes78 in the
British Journal of Diseases of the Chest. Desatura-
tion during a 6-min walk to o88% is also another
clinically useful marker of poor prognosis, and adds
to the predictive ability of serial changes in
physiology.79 Others have suggested that a novel
measure, the ‘‘distance-saturation product’’ i.e.
product of the distance walked and lowest oxygen
saturation during the 6-min walk test, is slightly
more accurate that either parameter alone, in
predicting mortality.80 Desaturation on exercise
should also prompt an echocardiogram, looking
for evidence of co-existing secondary pulmonary
arterial hypertension.81 This is highly relevant,
given a systolic pulmonary artery pressure on
cardiac echocardiogram of450mmHg is associated
with a 1-year survival rate of 45%, compared to a
pulmonary artery pressure ofo50mmHg which has
a 1-year survival rate of 83%.82
The pattern of features seen on HRCT is also
useful in assessing prognosis, patients with a scan
typical of UIP/IPF experiencing the highest mortal-
ity.75 HRCT ﬁndings also add prognostic information
to the histological diagnosis of UIP/IPF; survival is
worse in patients with histological UIP if they also
have a HRCT pattern felt by an expert radiologist to
ARTICLE IN PRESS
Stratify disease severity 
Gas transfer < 40% predicted 
Yes No
Refer + “standard” therapy7
Listed
Gas transfer > 40% predicted 
Clinical trial appropriate? 
Yes No
Trial “Standard” therapy (6 month trial) 7
Not listed
  3 monthly clinic review 
(symptoms, CXR, PFTs) 
Stable BetterWorse
Continue  
Other general issues 
Smoking cessation 
Osteoporosis prophylaxis / bone densitometry 
Vaccinations (influenza, pneumococcal) 
Oxygen (including ambulatory assessment) 
Pulmonary rehabilitation 
Screen for depression and coexisting cardiac disease, including 
pulmonary hypertension 
Palliative care if deteriorating and no surgical / trial options 
IPF confirmed7
Single lung transplant appropriate? 
Stop treatment or consider alternative7
≥
Figure 2 Simple management algorithm for IPF. Refer to text for details.
O.J. Dempsey1876be ‘‘deﬁnite’’ or ‘‘probable’’ UIP, compared with
patients with histological UIP, but an atypical HRCT
pattern for UIP.75Management
This is comprehensively reviewed in current ERS/
ATS guidelines.7 A simple overview is provided in
Fig. 2.56 If patients are clinically stable, with
‘‘limited’’ disease i.e. gas transfer 440% pre-
dicted, many clinicians would suggest that it is
reasonable to adopt a ‘‘watch-and-wait’’ policy,
assessing patients frequently over the next 6–12
months and only considering potentially toxic drugtherapy if there was evidence of clinical, radi-
ological or physiological deterioration. If, during
this initial assessment phase, patients demonstrate
disease progression i.e. FVC fall 410% over 6
months and/or desaturation o88% during a 6-min
walk, then referral for single lung transplant
assessment should be considered, assuming other-
wise medically appropriate.56,83
If patients have advanced disease i.e. gas
transfer o39% predicted, they should similarly be
referred for single lung transplant assessment.56,83
Ideally, all patients should be considered for
participation in a placebo-controlled trial, and
some current phase II/III trials are summarised in
Tables 2 and 3. Treatment with combination
immunosuppressant therapy (prednisolone plus
ARTICLE IN PRESS
Idiopathic pulmonary ﬁbrosis 1877azathioprine) +/ anti-oxidant therapy i.e.
N-acetylcysteine, can be considered at any stage,7
although as discussed later in this review, evidence
for corticosteroid and immunosuppressant therapy
is not persuasive, and patients should be aware of
this.12,13
Other areas of management that should not be
neglected include oxygen therapy (domiciliary
and ambulatory),84,85 pulmonary rehabilitation,86
nutrition, osteoporosis prophylaxis,87,88 smoking
cessation, assessment and treatment of common
co-morbidities such as cardiovascular disease,
psychological support for impaired quality of life
89 and ultimately palliative care. Space precludes a
more detailed discussion, but key references are
cited above.Role of oral corticosteroids
This is a question that has been comprehensively
examined in the medical literature, and the short
answer is ‘‘probably not’’.12,90 In 1944, Hamman
and Rich10 described four cases of a previously
unrecognised fatal pulmonary disease, charac-
terised by increasing breathlessness, which they
called ‘‘acute diffuse interstitial ﬁbrosis’’ of the
lungs. With the introduction of cortisone 4 years
later, in 1948, it is perhaps not surprising that
clinicians enthusiastically embraced this new ther-
apy, given the dismal prognosis associated with the
newly describe ‘‘Hamman–Rich’’ syndrome (which
would now be classiﬁed as AIP). Early experience
with cortisone, however, was disappointing. This is
highlighted in a review article from 1959, published
in the British Journal of Diseases of the Chest
(a forerunner of Respiratory Medicine).91
One would have hoped and anticipated that
steroid therapy would halt and reverse the
interstitial ﬁbrotic changes in the lungs which
produce such a distressing illness with ultimate
death from asphyxia and right heart failure, but
experience has shown them to be of little value.
Despite this initial pessimism, over the next few
decades corticosteroids became increasingly ac-
cepted as standard therapy, with small case series
and uncontrolled studies suggesting a useful sub-
jective and objective response.90 These early
studies were, in retrospect, poorly designed, and
the favourable response to oral corticosteroid likely
reﬂected inclusion of patients with more steroid
responsive interstitial disease, such as NSIP. The
importance of careful histological classiﬁcation,
and its impact on response to corticosteroidtherapy, is now well recognised. In a recent
Cochrane review, the efﬁcacy of corticosteroids in
adult patients with IPF was examined. Fifteen
studies were potentially eligible, but were ex-
cluded because of inadequate methodologies.12
The authors concluded that that currently there is
no evidence to support the routine use of corticos-
teroids as monotherapy in the management of IPF.
It is important also to remember the considerable
toxicity related to corticosteroid therapy. In a
prospective study of 41 patients with previously
untreated biopsy proven IPF, all patients experi-
enced at least 1 steroid-induced effect.92 Despite
this, in patients in whom a diagnosis of IPF is not
certain, it is still reasonable to try an empirical trial
of oral corticosteroid (+/ azathioprine) and it is
sobering to note that similar views were expressed
in the British Journal of Diseases of the Chest over
40 years ago!91
No other treatment apart from oxygen, digitalis,
diuretics and antibiotics for superadded infec-
tions can, however, be offered and steroids must
always be given a trial.Role of immunomodulatory agents
A recent Cochrane review has assessed the effect of
immunomodulatory agents in the treatment of
IPF.13 Fifty-nine studies were identiﬁed, published
up until April 2003, but quality was generally poor,
and only three randomised controlled trials were
suitable for meta-analysis,70,93,94 with two lesser
quality randomised controlled trials included in
discussion only.95,96 The authors concluded there
was little good-quality information regarding the
efﬁcacy of non-corticosteroid agents in IPF, and
little justiﬁcation for their routine use in the
management of IPF.13Possible future therapies
Our increasing understanding of the pathogenesis
of IPF has led to the development of a vast array of
potential new therapies. These have been compre-
hensively reviewed elsewhere, space precluding a
more detailed discussion here.14,45 In future, it may
be that a combination of therapies, similar to the
management of other chronic diseases, may be
employed, such as an anti-oxidant e.g. N-acetyl
cysteine, in conjunction with an anti-ﬁbrotic agent
e.g. pirfenidone. An overview of published, rando-
mised, placebo-controlled trials in IPF is presented
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O.J. Dempsey1882in Table 2, with current phase II/III trials presented
in Table 3.Conclusions
These are exciting times in IPF. While much remains
to be discovered, we are now beginning to unravel
the pathogenesis of this deadly disease. As a result,
new therapies are beginning to be developed which
are being assessed in suitably powered multicentre
trials. It is to be hoped that when the next
Centennial Review is published in Respiratory
Medicine, in 2107, its author will regard IPF as
historical curiosity, and a disease that is either
preventable, or at the very least, eminently
treatable.Acknowledgement
Special thanks to Dr. Andrea Chapman (Consultant
Pathologist) for the picture of a ﬁbroblastic focus.References
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